Tilt Biotherapeutics Ltd.
Clinical trials sponsored by Tilt Biotherapeutics Ltd., explained in plain language.
-
Virus plus immunotherapy shows promise against resistant ovarian cancer
Disease control OngoingThis early-stage trial tests a specially designed virus (TILT-123) that targets and kills cancer cells while also boosting the immune system. It is given together with the immunotherapy drug pembrolizumab (Keytruda) and sometimes chemotherapy, to women with ovarian cancer that no…
Phase: PHASE1, PHASE2 • Sponsor: TILT Biotherapeutics Ltd. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Experimental virus and immune cell combo targets hard-to-treat melanoma
Disease control OngoingThis early-stage trial tests a new approach for people with advanced melanoma that has not responded to other treatments. It combines a specially designed virus (TILT-123) that targets cancer cells, chemotherapy, and the patient's own immune cells grown in a lab. The main goal is…
Phase: PHASE1 • Sponsor: TILT Biotherapeutics Ltd. • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Experimental virus therapy takes on drug-resistant lung cancer
Disease control OngoingThis early-stage trial tests a new treatment for people with advanced non-small cell lung cancer that no longer responds to standard immunotherapy. The treatment combines a specially designed virus (TILT-123) that targets cancer cells with pembrolizumab, an immunotherapy drug. Th…
Phase: PHASE1 • Sponsor: TILT Biotherapeutics Ltd. • Aim: Disease control
Last updated May 12, 2026 13:43 UTC